Your browser doesn't support javascript.
loading
How I treat Parkinson's disease.
Barbosa, Egberto Reis; Limongi, João Carlos Papaterra; Chien, Hsin Fen; Barbosa, Pedro Melo; Torres, Marcela Reuter Carréra.
Afiliação
  • Barbosa ER; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo, SP, Brazil.
  • Limongi JCP; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo, SP, Brazil.
  • Chien HF; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo, SP, Brazil.
  • Barbosa PM; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo, SP, Brazil.
  • Torres MRC; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo, SP, Brazil.
Arq Neuropsiquiatr ; 80(5 Suppl 1): 94-104, 2022 05.
Article em En | MEDLINE | ID: mdl-35976316
BACKGROUND: Parkinson's disease (PD) is a complex neurodegenerative condition. Treatment strategies through all stages of disease progression could affect quality of life and influence the development of future complications, making it crucial for the clinician to be on top of the literature. OBJECTIVE: This paper reviews the current treatment of PD, from early to advanced stages. METHODS: A literature review was conducted focusing on the treatment of PD, in the different stages of progression. RESULTS: Every individual with a new diagnosis of PD should be encouraged to start exercising regularly. In the early stage, treatment should focus on using the lowest dose of levodopa or combination therapy that provides maximum functional capacity, and does not increase the risk of complications, such as peak dose dyskinesias and impulse control disorders. At the moderate and advanced stages, motor fluctuations and complications of treatment dominate the picture, making quality of life one important issue. Rehabilitation programs can improve motor symptoms and should be offered to all patients at any stage of disease progression. CONCLUSION: Many factors need to be considered when deciding on the best treatment strategy for PD, such as disease progression, presence of risk factors for motor and behavioral complications, potential side effects from dopaminergic therapy and phenotypical variabilities. Treatment should focus on functional capacity and quality of life throughout the whole disease course.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Discinesias Tipo de estudo: Risk_factors_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Arq Neuropsiquiatr Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Discinesias Tipo de estudo: Risk_factors_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Arq Neuropsiquiatr Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Alemanha